# Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

> **NCT03748199** · PHASE1,PHASE2 · COMPLETED · sponsor: **Santhera Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** POL6014
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03748199
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-08
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748199, "Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03748199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*